Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
Identifieur interne : 001373 ( Istex/Corpus ); précédent : 001372; suivant : 001374Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
Auteurs : Terence K. Y. Lai ; Philip Seeman ; Fang LiuSource :
- Synapse [ 0887-4476 ] ; 2012-03.
English descriptors
- KwdEn :
Abstract
The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/syn.21504
Links to Exploration step
ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><author><name sortKey="Lai, Terence K Y" sort="Lai, Terence K Y" uniqKey="Lai T" first="Terence K. Y." last="Lai">Terence K. Y. Lai</name><affiliation><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation></affiliation></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><affiliation><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/syn.21504</idno><idno type="url">https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001373</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001373</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><author><name sortKey="Lai, Terence K Y" sort="Lai, Terence K Y" uniqKey="Lai T" first="Terence K. Y." last="Lai">Terence K. Y. Lai</name><affiliation><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation></affiliation></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</mods:affiliation></affiliation></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><affiliation><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-03">2012-03</date><biblScope unit="volume">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="273">273</biblScope><biblScope unit="page" to="276">276</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">81863FAAD26024D36B1A1169200BA0AD59D74794</idno><idno type="DOI">10.1002/syn.21504</idno><idno type="ArticleID">SYN21504</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antipsychotics</term><term>erythrocytes</term><term>haloperidol</term><term>metoclopramide</term><term>red cell membrane</term><term>schizophrenia</term><term>tardive dyskinesia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Terence K.Y. Lai</name><affiliations><json:string>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</json:string></affiliations></json:item><json:item><name>Philip Seeman</name><affiliations><json:string>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</json:string><json:string>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</json:string><json:string>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</json:string></affiliations></json:item><json:item><name>Fang Liu</name><affiliations><json:string>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>antipsychotics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>metoclopramide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tardive dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>schizophrenia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>haloperidol</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>erythrocytes</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>red cell membrane</value></json:item></subject><articleId><json:string>SYN21504</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>shortCommunication</json:string></originalGenre><abstract>The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</abstract><qualityIndicators><score>5.296</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1755</abstractCharCount><pdfWordCount>2296</pdfWordCount><pdfCharCount>14990</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>257</abstractWordCount></qualityIndicators><title>Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><genre><json:string>brief-communication</json:string></genre><host><title>Synapse</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1098-2396</json:string></doi><issn><json:string>0887-4476</json:string></issn><eissn><json:string>1098-2396</json:string></eissn><publisherId><json:string>SYN</json:string></publisherId><volume>66</volume><issue>3</issue><pages><first>273</first><last>276</last><total>4</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Short Communication</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/syn.21504</json:string></doi><id>81863FAAD26024D36B1A1169200BA0AD59D74794</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2011 Wiley Periodicals, Inc.</p></availability><date>2012</date></publicationStmt><notesStmt><note type="content">*Conflict of interest: Coauthor PS is an advisor to Clera, a pharmaceutical company.</note><note>Centre for Addiction and Mental Health</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><author xml:id="author-1"><persName><forename type="first">Terence K.Y.</forename><surname>Lai</surname></persName><affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">Philip</forename><surname>Seeman</surname></persName><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</affiliation><affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</affiliation><affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</affiliation></author><author xml:id="author-3"><persName><forename type="first">Fang</forename><surname>Liu</surname></persName><affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</affiliation></author></analytic><monogr><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="pISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><idno type="DOI">10.1002/(ISSN)1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-03"></date><biblScope unit="volume">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="273">273</biblScope><biblScope unit="page" to="276">276</biblScope></imprint></monogr><idno type="istex">81863FAAD26024D36B1A1169200BA0AD59D74794</idno><idno type="DOI">10.1002/syn.21504</idno><idno type="ArticleID">SYN21504</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>antipsychotics</term></item><item><term>metoclopramide</term></item><item><term>tardive dyskinesia</term></item><item><term>schizophrenia</term></item><item><term>haloperidol</term></item><item><term>erythrocytes</term></item><item><term>red cell membrane</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Short Communication</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-09-26">Received</change><change when="2011-10-13">Registration</change><change when="2012-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1098-2396</doi><issn type="print">0887-4476</issn><issn type="electronic">1098-2396</issn><idGroup><id type="product" value="SYN"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="SYNAPSE">Synapse</title><title type="short">Synapse</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/syn.v66.3</doi><numberingGroup><numbering type="journalVolume" number="66">66</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2012-03">March 2012</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/syn.21504</doi><idGroup><id type="unit" value="SYN21504"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Short Communication</title><title type="tocHeading1">Short Communications</title></titleGroup><copyright ownership="publisher">Copyright © 2011 Wiley Periodicals, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2011-09-26"></event><event type="manuscriptAccepted" date="2011-10-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-03"></event><event type="publishedOnlineAccepted" date="2011-10-27"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-11-29"></event><event type="firstOnline" date="2011-11-29"></event><event type="publishedOnlineFinalForm" date="2012-01-03"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">273</numbering><numbering type="pageLast">276</numbering></numberingGroup><correspondenceTo>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:SYN.SYN21504.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="26"></count><count type="wordTotal" number="2460"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia <link href="#fn1"></link></title><title type="short" xml:lang="en">Metoclopramide Disruption of Cell Membranes</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Terence K.Y.</givenNames><familyName>Lai</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2 #af3" corresponding="yes"><personName><givenNames>Philip</givenNames><familyName>Seeman</familyName></personName><contactDetails><email>Philip.seeman@utoronto.ca</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Fang</givenNames><familyName>Liu</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CA" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">antipsychotics</keyword><keyword xml:id="kwd2">metoclopramide</keyword><keyword xml:id="kwd3">tardive dyskinesia</keyword><keyword xml:id="kwd4">schizophrenia</keyword><keyword xml:id="kwd5">haloperidol</keyword><keyword xml:id="kwd6">erythrocytes</keyword><keyword xml:id="kwd7">red cell membrane</keyword></keywordGroup><fundingInfo><fundingAgency>Centre for Addiction and Mental Health</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Conflict of interest: Coauthor PS is an advisor to Clera, a pharmaceutical company.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Metoclopramide Disruption of Cell Membranes</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title></titleInfo><name type="personal"><namePart type="given">Terence K.Y.</namePart><namePart type="family">Lai</namePart><affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philip</namePart><namePart type="family">Seeman</namePart><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</affiliation><affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</affiliation><affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fang</namePart><namePart type="family">Liu</namePart><affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="shortCommunication"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-03</dateIssued><dateCaptured encoding="w3cdtf">2011-09-26</dateCaptured><dateValid encoding="w3cdtf">2011-10-13</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">26</extent><extent unit="words">2460</extent></physicalDescription><abstract lang="en">The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</abstract><note type="content">*Conflict of interest: Coauthor PS is an advisor to Clera, a pharmaceutical company.</note><note type="funding">Centre for Addiction and Mental Health</note><subject lang="en"><genre>keywords</genre><topic>antipsychotics</topic><topic>metoclopramide</topic><topic>tardive dyskinesia</topic><topic>schizophrenia</topic><topic>haloperidol</topic><topic>erythrocytes</topic><topic>red cell membrane</topic></subject><relatedItem type="host"><titleInfo><title>Synapse</title></titleInfo><titleInfo type="abbreviated"><title>Synapse</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Short Communication</topic></subject><identifier type="ISSN">0887-4476</identifier><identifier type="eISSN">1098-2396</identifier><identifier type="DOI">10.1002/(ISSN)1098-2396</identifier><identifier type="PublisherID">SYN</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>273</start><end>276</end><total>4</total></extent></part></relatedItem><identifier type="istex">81863FAAD26024D36B1A1169200BA0AD59D74794</identifier><identifier type="DOI">10.1002/syn.21504</identifier><identifier type="ArticleID">SYN21504</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001373 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001373 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794
|texte= Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
}}
| This area was generated with Dilib version V0.6.29. |  |